| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EDITORIAL FOCUS
1Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; 2Pediatric Hematology, Marian Anderson Comprehensive Sickle Cell Center, Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania; 3Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland
SICKLE CELL PATHOPHYSIOLOGY comprises a complex interplay of episodic vasoocclusive events, ischemia-reperfusion injury, overproduction of reactive oxygen species (ROS), inflammation, endothelial activation, and hemolysis, all somehow driven by a single amino acid substitution in the β-globin chain of hemoglobin. Hemolysis and oxidative stress act synergistically to promote vascular dysfunction in sickle cell disease (SCD). As a result of chronic hemolysis, levels of free plasma hemoglobin are increased at baseline and nitric oxide (NO) bioavailability is diminished, producing endothelial dysfunction that has been linked to chronic vasculopathic complications of SCD such as pulmonary hypertension, cutaneous leg ulceration, priapism, and sudden death (14, 18, 19, 22, 23, 25).
NO regulates vasorelaxation and also possesses antioxidant, antiadhesive, and antithrombotic properties (33). NO is produced from the substrate L-arginine by endothelial nitric oxide synthase (eNOS) and mediates vasorelaxation through a paracrine action on vascular smooth muscle cells underlying the endothelium. Endothelial dysfunction, characterized by impaired vascular responsiveness resulting from decreased NO bioavailability, is associated with atherosclerosis, diabetes mellitus, hypertension, hypercholesterolemia, smoking, and obesity, illustrating the central importance of NO in the physiological regulation of vasomotor activity (3, 6).
Unlike coronary artery disease and its risk factors, which are associated with an impaired production of NO, SCD and other hemolytic diseases are characterized by a primary resistance to the action of NO (10, 13, 25, 29). The NO resistance state observed in SCD is multifaceted, with at least two major mechanisms contributing to impaired NO homeostasis: 1) scavenging of NO by cell-free plasma hemoglobin, and 2) oxidant stress due to the generation of ROS by both enzymatic and nonenzymatic pathways (11, 13, 19, 25). Hemolysis "unpackages" the red blood cell (RBC), releasing free hemoglobin into the plasma. No longer compartmentalized by the intact cell membrane, cell-free plasma hemoglobin rapidly reacts with and scavenges endothelial NO. Hemolysis further impairs NO bioavailability through the release of arginase from the RBC, which competes with NO synthase (NOS) for the substrate arginine. Arginase I levels and activity correlate with measures of intravascular hemolysis in patients with SCD, and notably the lowest ratios of arginine to ornithine are associated with pulmonary hypertension and prospective mortality (19, 20). The depletion of arginine leads to the functional uncoupling of NOS, whereby superoxide is preferentially formed over NO, amplifying the conditions of oxidant stress (33).
In their study, Kaul and colleagues (16) examine the mechanism of sickle cell vasculopathy in a transgenic mouse model of severe SCD and find robust correlations between in vivo NO resistance, measured by vasodilatory response to topical application of the NO donor sodium nitroprusside (SNP), hemolytic rate, and ROS generation. They present further evidence that arginine supplementation improves vascular function by ameliorating hemolysis, oxidant stress, and the NO resistance state.
The assessment of vascular reactivity in the sickle cell transgenic mouse revealed significantly blunted responses to both acetylcholine (ACh) and SNP, as well as blunted changes in mean arterial pressure (MAP) in response to NG-nitro-L-arginine methyl ester (L-NAME), consistent with a global impairment in the NO axis and, more specifically, a resistance to NO vasodilatory activity (evidenced by the lack of response to an exogenous NO donor) (13, 15). The authors confirm their previous findings of compensatory increases in eNOS and cyclooxygenase-2 protein expression in the sickle cell transgenic mouse, as well as increased baseline arteriolar vasodilation (15), indicating a potential compensatory upregulation of non-NO-dependent vasodilators (prostacyclin) in response to diminished NO bioavailability.
Interestingly, arginine treatment in the sickle cell mouse reversed the NO resistance, such that responses to ACh and SNP were augmented following arginine treatment, with increased MAP in response to L-NAME, indicating an increased basal and stimulated NO bioavailability.
This study demonstrates striking correlations between hemolytic rate and markers of oxidant stress in the transgenic sickle cell mouse, including novel findings of tight associations between plasma hemoglobin and both tyrosine nitration and blunted SNP responsiveness. Arginine supplementation led to improved vascular responsiveness to both endothelium-dependent and -independent vasodilation, suggesting that arginine was directly correcting the primary NO resistance state. This treatment effect was associated with a 50% reduction in plasma hemoglobin and a significant decrease in tyrosine nitration, suggesting both reduced hemolysis and oxidant stress, respectively. These findings illuminate the complex interactions of hemolysis and oxidant stress in potentiating vascular dysfunction (Fig. 1).
|
However, data from the NO biochemistry field suggests that the major pathway to protein nitration in vivo is via heme-mediated peroxidase chemistry (9, 24, 31). Any heme capable of Fenton-type chemistry can exert peroxidase chemistry, which in the presence of nitrite will generate nitrogen dioxide and nitrate tyrosine residues. Indeed, the myeloperoxidase knockout mouse exhibits significant reductions in protein nitration in vivo (5, 35). We would therefore propose that the high correlation between plasma hemoglobin and protein nitration in the current study by Kaul and colleagues (16) indicates that plasma hemoglobin may be driving the protein nitration rather than the superoxide-NO reaction, which forms peroxynitrite.
We would further argue that the role of hemolysis and plasma hemoglobin in fueling oxidant stress is underappreciated, creating a "chicken or the egg" dilemma as to whether oxidant stress (which leads to RBC damage and subsequent hemolysis) or hemolysis (which releases heme and free iron, powerful catalysts of ROS generation) is central to sustaining the vicious cycle of damage incited by hemoglobin S polymerization (Fig. 1). Although the association does not indicate causality, we propose the results of the current study are more consistent with hemolysis driving ROS formation and protein nitration. Intravascular hemolysis generates free heme and redox active metals, which participate in peroxidase chemistry (leading to lipid peroxidation), Fenton-type chemistry, and autooxidation chemistry (31). Thus these free heme and redox metals can mediate protein nitration under a greater range of conditions than peroxynitrite. Moreover, the uptake of plasma free heme or heme released by methemoglobin into endothelial cells promotes cellular damage, increasing the susceptibility to oxidant damage, and may directly activate xanthine oxidase and NADPH oxidase (2). Further evidence lending support to a predominant role of hemolysis is the increased heme oxygenase-1 (HO-1) expression in transgenic sickle cell mice (4), a finding confirmed in this study. The liberation of free heme by hemolysis induces the expression of HO-1, which scavenges the heme, thereby preventing its participation in redox reactions (8). This compensatory response to the increased heme burden degrades heme into iron, which is scavenged by ferritin, and carbon monoxide and biliverdin, which exhibit antioxidative properties of their own. Rather than serving as a marker of non-NO vasodilatory activity, we suggest HO-1 better reflects the extent of hemolysis. The decrease in plasma hemoglobin and the associated decrease in HO-1 expression following treatment with arginine suggest a direct effect of arginine on reducing the hemolytic rate.
In this model, arginine therapy reduces hemolysis and oxidant stress and normalizes the responsiveness to NO. This observation should be further explored to better elucidate the primary mechanism of action in targeting these tightly linked processes. Does arginine inhibit oxidant stress through increased erythrocytic glutathione and glutamine (an intraerthyrocytic antioxidant) and NOS recoupling (by restoring arginine availability), thereby reducing hemolysis secondary to (reduced) free oxygen radical-induced damage (13, 21)? Or, is the primary effect of arginine the result of decreased hemolysis via the inhibition of the endothelin-1/Gardos channel pathway, thus decreasing free heme and iron and removing the catalyst for lipid peroxidation, nitration, and autooxidation (27, 28)? Will dissecting these interrelationships allow us to better design combinations of therapies that effectively disrupt the cycle of hemolysis and oxidant injury?
Previous studies of arginine supplementation in experimental animal models and patients with SCD have produced variable results. Increased NO bioavailability after the BERK sickle mouse was treated with L-arginine was associated with the reduction in lipid peroxidation and augmented antioxidant activity (7). This treatment was also found to reduce RBC density via a NO-dependent downregulation of the Gardos channel (likely via an intermediate effect of endothelin receptors on RBCs) (26). Arginine treatment of patients with SCD increases plasma NO metabolite levels and acutely reduces pulmonary artery pressures (20). Recently, the enthusiasm for the clinical application of arginine for patients with SCD has been tempered by the results of a multicenter, blinded, phase II clinical trial. Presented in abstract form, arginine supplementation in pediatric patients with SCD at 0.05 or 0.1 g·kg–1·day–1 failed to raise blood arginine levels or show significant changes in laboratory indexes of clinical benefit (30). However, the doses of arginine were notably lower than the typical dosing in the cardiovascular field, and the lack of measurable increase in blood arginine levels suggests that a pharmacological dose of arginine was not achieved. An assessment of efficacy cannot be made with a homeopathic dosing regimen. Questions remain as to whether a higher dose of arginine might have been more effective or whether a lack of effect is due to a lesser degree of arginine deficiency in a pediatric population. Based on the findings of this study by Kaul and colleagues (16), we would propose targeting arginine therapy to patients with SCD with hyperhemolysis and elevated endothelin-1 levels, as these patients may potentially derive the most therapeutic benefit.
Further insight into the cause-and-effect relationship between hemolytic rate and oxidant stress is applicable to our understanding of the mechanisms driving other hemolytic disease states. The data suggest a role for hemolysis in the pathogenesis of endothelial dysfunction in many of these diseases; for example, pulmonary hypertension is a common complication of several chronic and hereditary hemoglobinopathies, including SCD, thalassemia major and intermedia, paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis, and microangiopathic hemolytic anemia (17). Low NO bioavailability has been implicated in the development of experimental cerebral malaria (12). In addition to decreased NO bioavailability, malaria and SCD share several features, including arginine depletion, endothelial dysfunction, increased expression of adhesion molecules, and microvascular occlusion, suggesting the possibility of a common mechanism of disease. A clinical study reported last year demonstrated the improved reactive hyperemia responses in individuals with moderately severe malaria and endothelial dysfunction following treatment with parenteral arginine, illustrating another example of a potential role for decreased arginine in impaired NO bioavailability in human disease (34).
As this article highlights, hemolysis and oxidative stress are intricately coupled in promoting vascular dysfunction, leaving the uncertainty about the primary mechanism (i.e., the chicken or the egg). These relationships and the ameliorating role of arginine are highlighted in Fig. 1. Several potential approaches to dissect and establish the relative contributions of hemolysis versus oxidant stress to endothelial dysfunction can be proposed. Murine models deficient in components of antioxidant systems could be transplanted with bone marrow from transgenic sickle cell mice, assessing for relationships between vasoreactivity, plasma hemoglobin, and protein nitration, as was performed in Fig. 6 of the study (16). Additionally, mice could be supplemented with an excess of antioxidants and hemolysis induced at different rates, by different mechanisms (e.g., alloimmune, RBC membrane defect, sickle, or thalassemia). A reductionist approach might be to compare the effects of injecting the components released by hemolysis (free hemoglobin and RBC membrane fragments) at graded levels and compare them in mice with different levels of oxidant stress and antioxidant loading. Finally, in a spectrum of mice with different levels of oxidant stress, there can be a focus on acute versus chronic effects of hemolysis, acknowledging that HO-1 upregulation and other compensatory mechanisms can blunt some of the hemolytic effects.
In summary, Kaul and colleagues (16) verify the strong association of NO resistance in SCD with free hemoglobin and further our understanding by establishing an association of NO resistance with oxidant stress. This connection should challenge us to consider hemolysis as the driving force sustaining the polymerization-induced cycle of hemolysis, decreased NO bioavailability, and oxidant stress underlying vascular dysfunction. Short of inhibiting the hemolytic rate, the inhibition of enzymatic generation of ROS alone may fail to effectively disrupt this vicious cycle in patients with SCD.
FOOTNOTES
Address for reprint requests and other correspondence: M. T. Gladwin, Pulmonary and Vascular Medicine Branch, NHLBI, Critical Care Medicine Dept., Clinical Ctr., NIH, Bldg. 10-CRC, Rm. 5-5140, 10 Center Dr., MSC 1454, Bethesda, MD 20892-1454 (e-mail: mgladwin{at}nih.gov)
REFERENCES
This article has been cited by other articles:
|
|
 |
|
  C. R. Morris Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia Hematology, January 1, 2008; 2008(1): 177 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Townes Gene Replacement Therapy for Sickle Cell Disease and Other Blood Disorders Hematology, January 1, 2008; 2008(1): 193 - 196. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
